These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87 related articles for article (PubMed ID: 25672914)
1. Delayed methotrexate excretion in infants and young children with central nervous system tumors and postoperative fluid collections. Cohen I Cancer Chemother Pharmacol; 2015 Apr; 75(4):875. PubMed ID: 25672914 [No Abstract] [Full Text] [Related]
2. Response to: comment on "Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections". Wright KD; Stewart CF Cancer Chemother Pharmacol; 2015 Apr; 75(4):877-8. PubMed ID: 25711766 [No Abstract] [Full Text] [Related]
3. Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections. Wright KD; Panetta JC; Onar-Thomas A; Reddick WE; Patay Z; Qaddoumi I; Broniscer A; Robinson G; Boop FA; Klimo P; Ward D; Gajjar A; Stewart CF Cancer Chemother Pharmacol; 2015 Jan; 75(1):27-35. PubMed ID: 25342291 [TBL] [Abstract][Full Text] [Related]
4. Effect of oral colestimide on the elimination of high-dose methotrexate in patients with primary central nervous system lymphoma--case report. Makino K; Kochi M; Nakamura H; Kuroda J; Honda Y; Ushio Y; Kuratsu J Neurol Med Chir (Tokyo); 2005 Dec; 45(12):650-2. PubMed ID: 16377955 [TBL] [Abstract][Full Text] [Related]
5. Delayed elimination of methotrexate in a patient receiving ciprofloxacin. Aouinti I; Gaïes E; Trabelsi S; Salouage I; Jebabli N; Charfi R; Lakhal M; Klouz A Therapie; 2013; 68(3):175-7. PubMed ID: 23886465 [No Abstract] [Full Text] [Related]
6. Extremely slow methotrexate elimination in a patient with t(9;22) positive acute lymphoblastic leukemia treated with imatinib. Van Hest RM; Schnog JB; Van't Veer MB; Cornelissen JJ Am J Hematol; 2008 Sep; 83(9):757-8. PubMed ID: 18615671 [No Abstract] [Full Text] [Related]
7. Carboxypeptidase G2 rescue after high-dose methotrexate. DeAngelis LM; Tong WP; Lin S; Fleisher M; Bertino JR J Clin Oncol; 1996 Jul; 14(7):2145-9. PubMed ID: 8683248 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of high-dose methotrexate in infants aged less than 12 months treated for aggressive brain tumors. Lucchesi M; Guidi M; Fonte C; Farina S; Fiorini P; Favre C; de Martino M; Sardi I Cancer Chemother Pharmacol; 2016 Apr; 77(4):857-64. PubMed ID: 26988222 [TBL] [Abstract][Full Text] [Related]
9. Central nervous system prophylaxis with high-dose methotrexate does not give rise to significant electroencephalographic changes in children with acute lymphoblastic leukemia. Korinthenberg R; Schneider A; Niemeyer C J Child Neurol; 2002 Jun; 17(6):409-12. PubMed ID: 12174959 [TBL] [Abstract][Full Text] [Related]
10. Systemic anaphylactic reaction following intrathecal administration of methotrexate in adult patient with primary central nervous system lymphoma. Elkiran ET; Altundag K; Aksoy S; Onal IK; Tekuzman G Am J Hematol; 2004 Apr; 75(4):265. PubMed ID: 15054831 [No Abstract] [Full Text] [Related]
11. Prevention of subdural fluid collections following transcortical intraventricular and/or paraventricular procedures by using fibrin adhesive. Al-Yamany M; Del Maestro RF J Neurosurg; 2000 Mar; 92(3):406-12. PubMed ID: 10701526 [TBL] [Abstract][Full Text] [Related]
12. Comment on: Toxicity profile of high-dose methotrexate in young children with central nervous system tumors. Cohen IJ Pediatr Blood Cancer; 2024 Nov; 71(11):e31270. PubMed ID: 39118228 [No Abstract] [Full Text] [Related]
13. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance. Joannon P; Oviedo I; Campbell M; Tordecilla J Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885 [TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of high-dose methotrexate after intravenous administration in pediatric patients with osteosarcoma. Colom H; Farré R; Soy D; Peraire C; Cendros JM; Pardo N; Torrent M; Domenech J; Mangues MA Ther Drug Monit; 2009 Feb; 31(1):76-85. PubMed ID: 19077931 [TBL] [Abstract][Full Text] [Related]
15. Treatment of primary CNS lymphoma with high-dose methotrexate in immunocompetent patients. Cohen IJ Pediatr Blood Cancer; 2011 Jul; 56(7):1151. PubMed ID: 21312324 [No Abstract] [Full Text] [Related]
16. Delayed renal excretion of methotrexate after a severe anaphylactic reaction to methotrexate in a child with osteosarcoma. Ozguven AA; Uysal K; Gunes D; Koroglu T; Gurcu O; Olgun N J Pediatr Hematol Oncol; 2009 Apr; 31(4):289-91. PubMed ID: 19346884 [TBL] [Abstract][Full Text] [Related]
17. Management of patients with primary central nervous system lymphoma treated with high-dose methotrexate. Warnick E; Auger D Clin J Oncol Nurs; 2009 Apr; 13(2):177-80. PubMed ID: 19349264 [TBL] [Abstract][Full Text] [Related]
18. Proceedings of the Workshop on Antimetabolites and the Central Nervous System (New York, NY, February 2-3, 1976): Introduction: antimetabolites and central nervous system neoplasia. Shapiro WR; Mehta BM; Hutchison DJ Cancer Treat Rep; 1977 Jul; 61(4):505-8. PubMed ID: 328143 [No Abstract] [Full Text] [Related]
19. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma. Edelman MJ; Meyers FJ; Houston J; Lauder I Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226 [TBL] [Abstract][Full Text] [Related]